By: Scott Davis
The knock on the “new” DHR is a company that pays bigger multiples, often seen as too big, for growth rates that are outsized. The obvious risk being that if growth rates don’t materialize, the deal model falls completely apart. And those who don’t believe in DHR see rising interest rates as a risk and see a company venturing into sexy product SKU’s (like Genomics) at a time where growth trades at unusually high multiples.
Note: Published April 19th, 2018